Navigation Links
Oxford Finance Corporation Provides a $2 Million Equipment Facility to Synta Pharmaceuticals Corp.
Date:4/14/2011

ALEXANDRIA, Va., April 14, 2011 /PRNewswire/ -- Oxford Finance Corporation (Oxford), a subsidiary of Sumitomo Corporation, today announced that it closed a $2 million equipment loan with Synta Pharmaceuticals Corp.  The funds will finance laboratory equipment used to manufacture compounds for use in Synta's ongoing clinical trials in the areas of oncology and chronic inflammatory diseases.

"Synta Pharmaceuticals has a diverse drug pipeline, including two leading cancer drugs currently in Phase 2 development in a broad range of indications," said Chad D. Norman, managing director for Oxford Finance.  "Oxford is very pleased to provide capital to support the development and delivery of Synta's novel pharmaceutical products."

About Oxford Finance Corporation

A subsidiary of Sumitomo Corporation, Oxford is a specialty finance firm providing senior secured loans to public and private life science and healthcare services companies worldwide. For over 20 years, Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets. In recent years, Oxford has originated over $1.5 billion in loans, with lines of credit ranging from $500 thousand to $40 million. Oxford is headquartered in Alexandria, Virginia, with additional offices in California, Massachusetts and North Carolina. For more information visit www.oxfordfinance.com.

About Synta Pharmaceuticals Corp.

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of
'/>"/>

SOURCE Oxford Finance Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Oxford BioTherapeutics Licenses BioWas POTELLIGENT® Technology for the Research and Development of its Therapeutic Antibodies in Cancer
2. ICAP Ocean Tomo Announces Four Patent Sets From Oxford Instruments - Each Represents an Important Advancement in Technology
3. Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation
4. Oxford Finance Corporation Hires Debbie Baker to Support Life Science Business Development in Western North America
5. Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals
6. Oxford Finance Corporation and United Orthopedic Group, Inc. Close $20 Million Credit Facility
7. Oxford Finance Corporation Facilitates Entry for Reata Pharmaceuticals into Asian Markets
8. Oxford Finance Corporation Closes $25 Million Credit Facility with EUSA Pharma
9. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
10. Cumberland Pharmaceuticals Appoints Rick S. Greene as Vice President, Finance & Accounting
11. Huifeng Bio-Pharmaceutical Technology Announces New Senior Vice President of Finance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... 22, 2013  Grifols, a global healthcare company based ... from a study demonstrating that a higher dose of ... levels of the alpha 1 protein in patients ... are considered within the normal range for healthy individuals. ... low levels of the alpha 1 proteinase inhibitor ...
(Date:5/22/2013)...  BD (Becton, Dickinson and Company) (NYSE: ... today the publication of its 2012 Sustainability Report ... continues to focus on the Company,s shared value approach ... of shared value — creating value for shareholders by ... are fundamental to our strategy," said Vincent ...
(Date:5/22/2013)... Calif. , May 22, 2013 Rigel ... the clinical advancement of three programs in development. The ... a JAK/SYK inhibitor, R348, being developed by Rigel as ... programs are aimed at oncology targets and are being ... under development by BerGenBio AS (BerGenBio) and a ligase ...
Breaking Medicine Technology:Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 4BD Issues 2012 Sustainability Report 2BD Issues 2012 Sustainability Report 3Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 2Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 3Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 4
... PTC Therapeutics, Inc. (PTC) today announced the appointment of ...  Dr. Spiegel served previously as Chief Medical Officer of ... Barth, M.D. to Vice President of Clinical Development.   ... report to Stuart W. Peltz, Ph.D., President and CEO ...
... -- Winner Medical Group Inc. (Nasdaq: ... medical dressings, medical disposables and non-woven fabric made ... announced that Mr. Jianquan Li, Winner Medical,s founder, ... the Distinguished Contribution award for 2010 by the ...
Cached Medicine Technology:PTC Therapeutics Appoints Robert Spiegel, M.D. as Chief Medical Officer 2PTC Therapeutics Appoints Robert Spiegel, M.D. as Chief Medical Officer 3Winner Medical CEO Awarded and Appointed Position by CNITA 2Winner Medical CEO Awarded and Appointed Position by CNITA 3Winner Medical CEO Awarded and Appointed Position by CNITA 4
(Date:5/22/2013)... WEDNESDAY, May 22 (HealthDay News) -- Roughly four in ... obstructive pulmonary disease (COPD) actually do not have the ... issue: Faulty diagnoses were made based on an evaluation ... "gold standard" disease test known as spirometry, which shows ... the amount of air they can exhale and how ...
(Date:5/22/2013)... New research from Brigham and Women,s Hospital (BWH) finds ... uncommon but deadly lung disease, may be effective in ... findings will be presented at the American Thoracic Society ... New England Journal of Medicine on May 22 ... edition., "While this variant of the MUC5B gene is ...
(Date:5/22/2013)... ATS 2013, PHILADELPHIA ─More than 40 percent of ... funded clinic did not have the disease, researchers ... diagnostic "gold standard" for chronic obstructive pulmonary disease. ... the under-diagnosis of COPD, there has not been ... of over-diagnosis," said Christian Ghattas, MD., MSc, ...
(Date:5/22/2013)... In the past decade, more ... courts with donated uniforms, shoes, balls and other ... to partnering with manufacturers to provide youth with sporting ... $8.8 million in sports and fitness equipment over 10 ... outfitted for physical activity. , An inaugural donation ...
(Date:5/22/2013)... Alabama (PRWEB) May 22, 2013 ... solutions to state Health and Human Services and ... of Mental Health (ADMH) selected the CoCENTRIX ... platform to manage the Health Records and coordinate ... psychiatric hospitals. , CoCENTRIX is transitioning the ...
Breaking Medicine News(10 mins):Health News:COPD May Be Over-Diagnosed Among Uninsured 2Health News:Genetic marker associated with risk for pulmonary fibrosis 2Health News:Study finds COPD is over-diagnosed among uninsured patients 2Health News:Study finds COPD is over-diagnosed among uninsured patients 3Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 2Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 3Health News:The State of Alabama Selects the CoCENTRIX Coordinated Care Platform to Facilitate Care for Its Citizens Treated in State Psychiatric Hospitals 2Health News:The State of Alabama Selects the CoCENTRIX Coordinated Care Platform to Facilitate Care for Its Citizens Treated in State Psychiatric Hospitals 3
... salon to help San Diego,s frantic families rid themselves of lice ... the head lice helpers, ( www.hairfairies.com ) today announced that it ... San Diego on May 12, 2009. , , ... salon dedicated to removing head lice. With salons in New ...
... May 12 Blue Cross and Blue Shield of ... an accreditation status of "Excellent" for its HMO products ... is an independent, non-profit organization that evaluates how well ... system -- physicians, hospitals, other providers and administrative services ...
... Manage Their Daily and Weekly MedicationsLAWRENCE, Mass., May 12 ... healthcare industry as a whole, it,s individual healthcare professionals ... a smaller scale.Goss, a medical technologist, enjoys her line ... good about what I do in the hospital lab," ...
... N.H., May 12 After very successful test marketing ... has begun selling its all-natural sports mints called Muscle ... and several electrolytes in a chewable mint, it is ... ingredients are used, and this is reflected in its ...
... PhD, FNP Join Together to Raise Awareness of Common, ... Fibromyalgia is often called an "invisible" illness because ... sick. However, something as simple as a hug ... fibromyalgia is one of the most common chronic, widespread ...
... Evidence-based, Unbiased Determinations Use Latest Clinical InformationLANSDALE, Penn., ... today equals 17 percent of the U.S. gross ... will equal 20 percent. Most politicians and healthcare ... inefficiencies, inflated prices, poor management and waste that ...
Cached Medicine News:Health News:Lice Removal Salon Offers San Diego an Upscale Solution to an Undesirable Problem 2Health News:NCQA Accreditation Status of Excellence Awarded to Blue Cross and Blue Shield of Georgia 2Health News:Healthcare Professional Is Working to Make a Difference, One Dose at a Time 2Health News:New Class of Sports Nutrition Product Launched 2Health News:VIDEO from Medialink, the National Fibromyalgia Association and Pfizer: The Painful Truth about Fibromyalgia 2Health News:IROs Help Cut Health Plan Costs During the Recession 2
... the serum tube is specially coated with ... coagulation process. Serum / gel tubes contain ... the tube; during centrifugation, this gel forms ... the blood cells. In the primary tube ...
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology....
The inner wall of the tube is coated with spray-dried lithium, ammonium or sodium heparin. These additives are anti-coagulants, which activate anti-thrombins, thus blocking the coagulation cascade of...
BD Vacutainer® Heparin Tubes are spray-coated with either lithium heparin or sodium heparin and are used for plasma determinations in chemistry....
Medicine Products: